Alva10 announces partnership with Diaceutics joining DXRX platform to focus on value based reimbursement for diagnostics to increase utilization and access for targeted therapies

Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients

Transformational Pathway to US Payer System; Attributing US$1.4 Billion Health and Economic Benefit from geneType Breast Cancer

Alva10 partners with Diaceutics, joining DXRX platform to drive for value-based reimbursement models for the US


Episode 5 - IQVIA MedTech Business Insights

Surfing the NASH Tsunami


Health Benefits Innovation

 Pittsburgh Business Group on Health 

Shift Shapers Podcast with David Saltzman: 

CC: Life Science

Precision Medicine podcast

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

Value-Based Pricing in In Vitro Diagnostics with Lena Chaihorsky

S4-12 – Deep Dive: ICER Draft Report on Resmetirom and Obeticholic Acid for NASH

Delivering Better Patient Care includes Preemptive Strategies
Pharmacy Podcast Network

“It’s all your Business”: “The Role of Diagnostics in Effective and Cost-Saving Healthcare” with Hannah Mamuszka and Lena Chaihorsky

“Get the RIGHT drug the FIRST time!” with Lena Chaihorsky 

The Difficulties of Diagnostic Development with Hannah Mamuszka and Chris Conner 

Then and Now: The Progress of Precision Medicine Diagnostics with Hannah Mamuszka and Lena Chaihorsky of Alva10

 Lena Chaihorsky presents the Alva10 process as an example of business model innovation dedicated to creating and commercializing diagnostics that will be highly valued and utilized by healthcare purchasers. Panel discussion with other business model innovators in the diagnostics sphere to follow. 
Agenda here.

monday MARCH 6, 2023 

Clinical Laboratory 2.0 Annual Meeting 
 "Business Models for Lab-Initiated Value-Based Care”

and recent appearances

Lena Chaihorsky leads a panel discussion on the early adopters of diagnostics and the pilot programs that can get valuable diagnostics through the toughest period of early commercialization. Join us! Agenda here.

monday october 24, 2022

Jumpstarting a Diagnostic Product Launch via Innovative Pilots with Forward-Thinking Payers and Providers


and recent appearances

Episode 5 - IQVIA MedTech Business Insights: Value-Based Pricing in In Vitro Diagnostics with Lena Chaihorsky Listen to full podcast HERE.

thursday september 29, 2022

IQVIA MedTech Business Insights


and recent appearances

Catch VP Lena Chaihorsky in conversation with Welldyne PBM’s Chief Medical Officer Nick Page about the innovative ways PBMs can engage with the diagnostic industry to support their own value propositions, and in so doing create an alternative market pathway for this critical category of healthcare tools.  Watch HERE.

tuesday august 23, 2022

The Role of Alternative Payers in the Adoption of a Diagnostic

Cambridge Healthtech Institute


Alva10 CEO Hannah Mamuszka and Erika Spaeth, PhD Director, Clinical Affairs, Phenogen Sciences discuss how a polygenic risk score for breast cancer can better assess risk for developing breast cancer than relying on BRCA status or family history alone. 85% of women who get breast cancer do not have a BRCA gene mutation and do not have family history of breast cancer.  Watch HERE.

thursday june 23, 2022

Beyond BRCA: A Polygenic Risk Score to Identify Patients at Elevated Risk for Breast Cancer

Precision Medicine Leadership Summit


Hannah Mamuszka and Blake Long, MD, of Alva10 join host Joe Selvaggi to discuss the role that Pharmacy Benefit Managers play in the high cost of prescription drugs in the US.  Listen HERE.

april, 2022

Pharmacy Benefit Managers & the cost of prescription drugs in the us



Lena Chaihorsky, Alva10’s VP of Payer Innovation reviews the hard truths about specialty drug efficacy rates and the ‘trial and error’ patterns of treating patients in the absence of diagnostics today, while offering solutions employers can implement today to decrease costs and improve outcomes. See the agenda HERE.

tuesday april 19, 2022

Ending Trial and Error Medicine: Why Your Drug Spend is So High

Pittsburgh Business Group


Join Lena Chaihorsky for a discussion around prioritizing reimbursement as an early–stage biotech start-up. Learn about the historic mistakes made in the industry and learn how to set yourself up for success directly from a payer. Register HERE.

tuesday march 1, 2022

Why Payers Can Make or Break Your Product + How To Partner for Success

Biocom California


Lena Chaihorsky joins a virtual panel discussion focused on understanding how to translate the national conversation around diagnostic importance into long term change for the diagnostic industry. See the agenda HERE.

tuesday september 21, 2021

COVID Momentum? Driving value and outcomes-based pricing in In Vitro Diagnostics

AdvaMed’s MedTech Conference


Lena Chaihorsky joins a panel discussion led by the Get the Medications Right (GTMRx) Institute to raise awareness among employers about the low efficacy and high cost of specialty drugs. Check out a recap of the conversation HERE.

thursday september 9, 2021

Health 2021 Employer-Led Healthcare Symposium

Pittsburgh Business Group


Explore where and why the status quo reimbursement model is not working for the diagnostics industry in a session with Lena Chaihorsky at the annual Q1 Diagnostic Coverage & Reimbursement Conference. Check out the annual Q1 conference series HERE.

Wednesday FEBRUARY 17, 2021

Flipping the Reimbursement Model

Q1 Productions


Our VP of Payer Innovation Lena Chairhorsky spoke on a panel discussing reimbursement models for gene and cell therapies, and how diagnostics could be instrumental in proving their value and creating a sustainable model that allows developers and patients to be successful. Full agenda HERE

Wednesday December 9, 2020

INVEST Precision Medicine



Lena Chaihorsky discusses how to align incentives and develop tests that payers want to pay for. Check out the Video HERE

December 15th 12-1:30 PT, December 17th 10-11:30 PT, and December 18th 10-11:30 PT

Illumina Payer Summit

on-demand with live events


UpCOMING & Recent appearances

Alva10 Videos

The pandemic has made everyone realize the importance of diagnostics in healthcare, but 8 months into the pandemic, we still lack the diagnostics we need to best manage Covid-19. How can we incentivize the development of the diagnostics we need to find disease, determine risk, and assess immunity? What are the regulatory barriers, and how can they be overcome? Who pays for these tests? What can we learn from Covid-19 for the next pandemic?

Diagnostics for Covid

How to Get What We Need

Diagnostic tests can be well validated, accepted in guidelines, and even reimbursed, yet they still don’t impact patient care. Why? Improper use, lack of physician understanding & support, lack of inclusion in coverage policies, inability to track all contribute to losing the potential impact of critical diagnostic tools. Software that highlights & streamlines decision making and provides information at the point of care allows for more efficient precision delivery of these tools.

Precision Medicine usually connotes use of diagnostics and other tools to optimize care in oncology, but really we should be considering development and use of these tools in every disease area. We will discuss the challenges around development and commercialization of Precision Medicine diagnostics for use in stroke and autoimmune diseases.

Hannah Mamuszka & Satabhisa Mukhopadhyay PhD, MS, Chief Scientific Officer & Founder, 4D Path discuss the potential for digital pathology to supplant IHC, PCR, FISH, & NGS in oncology, dramatically reducing cost & increasing patient access.

What is the potential for

Precision Medicine Outside of Oncolocy?

Precision Diagnostics 4D Path

Is it Possible to Obviate the Need for NGS Panels in Oncology with a Digital Solution?

How can Software Enable 

Diagnostics to Impact Patient Care?

October 2019— Hannah Mamuszka, CEO, Alva10 on Rethinking the Companion Diagnostic Deal Structure to Benefit All Stakeholders

Companion Diagnostics Forum

Companion Diagnostics are Bad for Diagnostic Companies


Registration Required for Access.